Mean amplitude values during a complete 360° rotation for the multifidus muscle. by Christoph Anders (4068499)

Summary statistics of key variables. by Saul Estrin (8629173)

“…We find that in developing countries, as urban economic density increases, innovation first increases and then begins to decrease beyond a certain point, with the decline being most prominent in the largest cities. …”

Craniocaudal impulses of fore- and hindlimbs at three bar heights during take-off. by Leena Inkilä (20614460)

Apoptosis inhibitor abolished and restored rTsSPc-disrupted Caco-2 monolayer barrier integrity. by Qi Qi Lu (17721401)

Subjects:

Inhibition of PGAM5 and apoptosis prevented <i>T. spiralis</i> larval invasion of Caco-2 monolayer. by Qi Qi Lu (17721401)

Subjects:

PGAM5 knockdown prevented rTsSPc from disrupting Caco-2 monolayer integrity. by Qi Qi Lu (17721401)

Subjects:

rTsSPc induced Caco-2 cell apoptosis. by Qi Qi Lu (17721401)

Subjects:

Inhibition of PGAM5 and apoptosis alleviated the rTsSPc-damaged Caco-2 monolayer barrier integrity. by Qi Qi Lu (17721401)

Subjects:

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Time course of optical coherence tomography and fundus findings in a representative non-recurrent eye. by Yasuyuki Sotani (20114144)

Subjects:

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

Subjects:

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Subjects:

Preoperative background characteristics of the patients. by Yasuyuki Sotani (20114144)

Subjects:

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)